TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03643679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kwit smartphone app
Description: The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
Study: NCT03078582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan (RA101495)
Description: 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilucoplan (RA101495)
Description: 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
Study: NCT00953108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine
Description: 300 mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: escitalopram 10 mg per day
Study: NCT03166813

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Preconditioning
Description: The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placement of blood pressure cuff without inflation for 30 minutes.
Study: NCT04054284

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antidiabetic Herbal Tea
Description: Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbal Tea
Description: Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
Study: NCT04544020

Intervention type: DIETARY_SUPPLEMENT
Intervention: NG feeding
Description: NG feeding
Study: NCT02772952

Intervention type: OTHER
Group type: OTHER
Intervention: Control Intervention
Description: Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention
Description: Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
Study: NCT01747122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wound catheter
Description: Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Study: NCT04854252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: TIVA opioid-containing anesthesia: fentanyl in a bolus dose of l3 mcg/kg (corrected weight) TIVA opioid-free anesthesia: dexmedetomidine 1-1.5 mcg/kg (corrected weight) for 40 minutes
Study: NCT03824990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement of management of neonatal jaundice
Description: During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality improvement of management of neonatal jaundice
Description: During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
Study: NCT02777918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipe provision
Description: 6 recipes will be provided every 2 weeks by post for 12 weeks
Study: NCT02428179

Intervention type: PROCEDURE
Intervention: StOP? - Control group
Description: Control group - Surgical procedure without Study Intervention
Study: NCT01680250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
Study: NCT03950622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5 mL dose.
Study: NCT02304055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
Study: NCT01854229

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometra Programmable Intrathecal Infusion Pump
Description: There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometra Programmable Intrathecal Infusion Pump
Description: There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
Study: NCT03977935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the second-generation MCCG
Description: Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
Study: NCT01587053

Intervention type: OTHER
Intervention: therapeutic education program
Study: NCT03241017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Immunotherapy with Durvalumab after ASCT
Study: NCT01224015

Intervention type: DRUG
Group type: OTHER
Intervention: normal saline
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 44 U
Description: 44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: onabotulinumtoxinA 24 U
Description: 24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
Study: NCT03062332

Intervention type: GENETIC
Intervention: Faecal genome
Description: Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.

Intervention type: GENETIC
Intervention: Faecal genome
Description: Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.

Intervention type: GENETIC
Intervention: Faecal genome
Description: Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.

Intervention type: GENETIC
Intervention: Faecal genome
Description: Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.

Intervention type: GENETIC
Intervention: Faecal genome
Description: Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.

Intervention type: GENETIC
Intervention: Faecal genome
Description: Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
Study: NCT03926442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Italian Herb meal
Description: Italian Herb in active breakfast meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinnamon Meal
Description: Cinnamon in active breakfast meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pumpkin Spice meal
Description: Pumpkin Spice Mix in active breakfast meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo meal
Description: Placebo in breakfast meal
Study: NCT01499992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard physical therapy program PLUS aquatic physical therapy
Description: 2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
Study: NCT03427216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen/diazepam
Description: Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal placebo
Description: Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
Study: NCT02685969

Intervention type: PROCEDURE
Intervention: 18F-Flutemetamol & 18F-FDG
Description: Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
Study: NCT03436277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sucralose
Description: Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
Study: NCT03051165

Intervention type: DEVICE
Group type: OTHER
Intervention: Hypoglossal Nerve Stimulation Treatment Withdrawal
Description: After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
Study: NCT04751838

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT01896310

Intervention type: DEVICE
Intervention: probe-based confocal laser endomicroscopy
Description: all patients will receive pCLE examination
Study: NCT03631953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib administered at a fixed dose (1.5 mg daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: A panel of 3 doses of ALPELISIB could be tested

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Therapeutic biomarkers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
Study: NCT02847689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language Treatment
Description: Recording of a mother's voice reading a children's storybook.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Treatment
Description: Standard of Care
Study: NCT02092116

Intervention type: DRUG
Group type: OTHER
Intervention: Romidepsin
Description: Latency reversing agent

Intervention type: DRUG
Group type: OTHER
Intervention: Romidepsin
Description: Latency reversing agent

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vacc-4x
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: rhuGM-CSF
Description: Granulocyte macrophage colony stimulating factor as a local adjuvant
Study: NCT00770757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-4047
Study: NCT00739141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
Description: Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
Study: NCT01264679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: IV Ferumoxytol
Study: NCT03482011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03074331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet(s) administered orally once daily
Study: NCT02428179

Intervention type: PROCEDURE
Intervention: StOP? - Intervention group
Description: Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
Study: NCT03648814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracameral injection
Description: A/C injection of 1.25 mg/0.05 mL bevacizumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal injection
Description: Vitreous injection of 1.25 mg/0.05 mL bevacizumab
Study: NCT03050918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Phone Call
Description: Patients will receive a first call attempt within 72 hours discharge.
Study: NCT02265172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy screening
Description: Physiotherapy screening.
Study: NCT03888248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Description: Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle strengthening exercises
Description: Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises
Description: Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
Study: NCT01604161

Intervention type: DRUG
Intervention: somatropin
Description: Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
Study: NCT02073578

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peroral Endoscopic Myotomy (POEM)
Description: Endoscopy myotomy for treatment of achalasia
Study: NCT02137070

Intervention type: PROCEDURE
Intervention: Bariatric Surgery Candidates
Description: Participants who are intending to have bariatric surgery for weight loss

Intervention type: OTHER
Intervention: Non surgical/Community volunteers
Description: Healthy adults with body mass index \>35 who will not undergo bariatric surgery for weight loss
Study: NCT02311725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aTAU + sTVi
Description: Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aTAU + Attention Control Videos
Description: Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
Study: NCT05035303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nor-Epinephrine injection versus saline during PCNL
Description: The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Nor-Epinephrine injection versus saline during PCNL
Description: The PCNL tract is infiltrated by Nor-Epinephrine or Normal Saline before its dilatation.
Study: NCT01074567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMSO cocktail
Description: intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
Study: NCT01319617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Description: Soft contact lens-based device intended for continuous recording of relative changes in IOP
Study: NCT01595061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo local core biopsy or surgical excision
Study: NCT00137995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m² D-2/D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m² D-2/D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m² D1-D2-D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatine
Description: max 800mg D2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide + Mesna
Description: 5 g/m² from D2 to D13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatine
Description: 100 mg/m² from D1 to D13
Study: NCT02496481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored brochure
Description: Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored brochure
Description: Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
Study: NCT01635010

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: continuous positive airway pressure (CPAP)
Description: CPAP pressure is individually prescript according to polysomnography for CPAP titration
Study: NCT03810001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mechanical Stimulation
Description: micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
Study: NCT03647436

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment. Both groups.
Description: Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment. Both groups.
Description: Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
Study: NCT01758965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPI
Description: monotherapy of PPI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: H2RA and surgicel
Description: combination therapy of H2RA and surgicel
Study: NCT02131012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Celecoxib
Description: 1-4 mg intravitreal celecoxib